1. Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure
- Author
-
Haegeun Song, Jong-Hwa Ahn, Min Gyu Kang, Kye-Hwan Kim, Jae Seok Bae, Sang Young Cho, Jin-Sin Koh, Yongwhi Park, Seok-Jae Hwang, Eun Jeong Cho, Kyeongmin Byeon, Sang-Wook Kim, Udaya S. Tantry, Paul A. Gurbel, Jin-Yong Hwang, and Young-Hoon Jeong
- Subjects
Hematology - Abstract
Background High-sensitivity C-reactive protein (hs-CRP) has been proposed as an indicator of inflammation and cardiovascular risk. However, little is known of the comparative temporal profile of hs-CRP and its relation to outcomes according to the disease acuity. Methods We enrolled 4,263 East Asian patients who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) and stable disease. hs-CRP was measured at baseline and 1 month post-PCI. Major adverse cardiovascular events (MACE: the composite occurrence of death, myocardial infarction, or stroke) and major bleeding were followed up to 4 years. Result The AMI group (n = 2,376; 55.7%) had higher hs-CRPbaseline than the non-AMI group (n = 1,887; 44.3%) (median: 1.5 vs. 1.0 mg/L; p Conclusion AMI patients have greater inflammation during the early and late phases than non-AMI patients. Risk phenotype of hs-CRPbaseline correlates with 1-month outcomes only in AMI patients. However, the prognostic implications of this risk phenotype appears similar during the late phase, irrespective of the disease acuity.
- Published
- 2023
- Full Text
- View/download PDF